Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
Rocco Capuano, Giovanna Donnarumma, Alvino Bisecco, Elena Grimaldi, Miriana Conte, Alessandro d’Ambrosio, Federica Matrone, Mario Risi, Riccardo Maria Borgo, Manuela Altieri, Federica Giuliano, Nicola Coppola, Massimiliano Galdiero, Gioacchino Tedeschi, Antonio Gallo
Topics & Concepts
MedicineNatalizumabMultiple sclerosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)ImmunologyVirology2019-20 coronavirus outbreakMessenger RNAInternal medicineDiseaseOutbreakInfectious disease (medical specialty)GeneBiochemistryChemistrySARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders